SCYX
Scynexis Inc
NASDAQ · Pharmaceuticals
$0.76
+0.07 (+9.94%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 10.03M | 9.68M | 11.00M |
| Net Income | 2.85M | 2.71M | 2.47M |
| EPS | — | — | — |
| Profit Margin | 28.5% | 28.0% | 22.5% |
| Rev Growth | +19.6% | +15.5% | +17.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.12M | 3.72M | 4.09M |
| Total Equity | 24.92M | 23.32M | 24.16M |
| D/E Ratio | 0.17 | 0.16 | 0.17 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 3.19M | 3.39M | 3.79M |
| Free Cash Flow | 2.29M | 1.90M | 2.29M |